HLB's Rivoceranib Liver Cancer Drug Manufacturing Facilities Pass FDA Review

HLB announced that a second manufacturing facility for its liver cancer treatment, rivoceranib, has successfully completed a U.S. Food and Drug Administration (FDA) regulatory review. This positive development addresses previous manufacturing concerns that had resulted in Complete Response Letters, thereby advancing the drug's approval process. This milestone is significant for HLB and patients awaiting new liver cancer therapies.